CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 8)

Average Co-Inventor Count = 4.3

ph-index = 15

Forward Citations = 553(Granted Patents)

Location History:

High Wycombe, GB (1992 - 2004)
Buckinghamshire, GB (1999 - 2010)
Berkshire, GB (2011)
Slough, GB (2012 - 2021)

Company Filing History:

19 out of 81

Celltech Therapeutics Limited

Years Active: 1992-2021

Loading Chart...

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10883996 - Methods of identifying signaling modulators of the trimeric TNFa (2021-01-05),

2. 10273247 - Imidazothiazole derivatives as modulators of TNF activity (2019-04-30),

3. 10087179 - Fused tricyclic imidazole derivatives as modulators of TNF activity (2018-10-02),

4. 9932343 - Fused tricyclic benzimidazoles derivatives as modulators of TNF activity (2018-04-03),

5. 9890174 - Fused Tricyclic imidazole derivatives as modulators of TNF activity (2018-02-13),

6. 9868749 - Fused imidazole and pyrazole derivatives as modulators of TNF activity (2018-01-16),

7. 9815797 - Fused bicyclic heteroaromatic derivatives as modulators of TNF activity (2017-11-14),

8. 8710054 - Fused thiazole derivatives as kinase inhibitors (2014-04-29),

9. 8338592 - Fused thiazole derivatives as kinase inhibitors (2012-12-25),

10. 8324204 - Fused thiophene derivatives as kinase inhibitors (2012-12-04),

11. 8242116 - Fused thiazole derivatives as kinase inhibitors (2012-08-14),

12. 8168634 - Thiazole derivatives as kinase inhibitors (2012-05-01),

13. 7888344 - Fused thiazole derivatives as kinase inhibitors (2011-02-15),

14. 7795256 - Thieno-pyridinone derivatives as kinase inhibitors (2010-09-14),

15. 6780874 - Enamine derivatives (2004-08-24),

Title: Rikki Peter Alexander: Innovator in TNF Signaling

Introduction: Rikki Peter Alexander, located in Slough, GB, is an accomplished inventor with a remarkable portfolio of 41 patents. His contributions to the field of biomedicine, particularly in tumor necrosis factor (TNF) signaling, have paved the way for innovative therapeutic approaches.

Latest Patents: Two of Rikki's latest patents highlight his groundbreaking work in modulating TNF activity. The first patent, "Methods of identifying signaling modulators of the trimeric TNFα," focuses on identifying compounds capable of modulating TNF signaling through its receptors. This invention offers potential therapeutic applications. The second patent, "Imidazothiazole derivatives as modulators of TNF activity," details substituted imidazo[2,1-b]thiazole derivatives that act as potent modulators of human TNFα activity. These compounds are poised to provide benefits in treating various ailments, including autoimmune and inflammatory disorders, neurological disorders, pain, cardiovascular issues, metabolic disorders, ocular conditions, and oncological problems.

Career Highlights: Rikki has built his career with significant contributions at Celltech Therapeutics Limited and Celltech R&D Limited. His dedication to research and development in these companies has further advanced the applications of TNF modulation in medicine.

Collaborations: Throughout his career, Rikki has collaborated with notable experts in the field, including Graham John Warrellow and John Clifford Head. These partnerships have enriched his research and fostered advancements in therapeutic developments.

Conclusion: Rikki Peter Alexander stands out as a pioneering inventor in TNF signaling, holding 41 patents that reflect his dedication to medical innovation. His work continues to influence the landscape of therapeutic strategies for a variety of human ailments, demonstrating the vital role of research in improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.